Safety and efficacy of Tofacitnib in patients with active psoriatic arthritis: Interim analysis of OPAL balance, an open-label, long-term extension study
Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the interim safety, tolerability, and efficacy of tofacitinib in PsA patients in OPAL Balance, a 3-year, open-label, long-term extension study (data cut-off: August 2017; database not locked, data may change).
Eligible patients from two phase (P) 3 (P3) tofacitinib PsA studies (OPAL Broaden, NCT01877668; O...
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, 2.9MB)
- Publisher copy:
- Copyright holder:
- Nash et al.
- Copyright date:
- Rights statement:
- © The Author(s) 2020. This article is published under an open access license.
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record